Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 2/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941954 | 0.77 | ATM (0.63) | PTGS2PTGS1MEN1KMT2AATM | |
| SCHEMBL30502883 | 0.77 | ATM (0.63) | PTGS2PTGS1MEN1KMT2AATM | |
| SCHEMBL699369 | 0.76 | MEN1 (0.41) | PTGS2PTGS1MEN1KMT2AATM | |
| SCHEMBL28242748 | 0.72 | TDP1 (0.52) | PTGS2ATMTDP1L3MBTL1PBRM1 | |
| SCHEMBL10072753 | 0.72 | GAA (0.53) | PTGS2PTGS1MEN1KMT2AL3MBTL1 | |
| SCHEMBL688497 | 0.72 | GAA (0.53) | PTGS2PTGS1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14232252 | 0.69 | ATM (0.55) | PTGS2PTGS1ATMTDP1L3MBTL1 | |
| SCHEMBL9490588 | 0.68 | L3MBTL1 (0.63) | PTGS2PTGS1ATMTDP1L3MBTL1 | |
| SCHEMBL688292 | 0.68 | ALDH1A1 (0.34) | CA1CA2MEN1KMT2AL3MBTL1 | |
| SCHEMBL687193 | 0.68 | CA1 (0.41) | CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1606248-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080951-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
| EP-1457485-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | PTGS2 873/4885PTGS1 148/4885STS 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.